Novartis AG Takes Retraction of JIKEI Paper “Seriously”; Problems Partly Traced to “Limited Understanding” about Investigator-Led Trials

Swiss pharmaceutical maker Novartis AG takes seriously the undeclared conflicts of interest and shaky data used in a key JIKEI Heart Study paper on Diovan (valsartan), the company said on September 6 on the heels of the article’s retraction the...read more